If you have been reading about melanogenesis and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-08-11. Where a claim depends on a specific study, the study is described rather than over-claimed.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Lyophilised melanotan-2 is comparatively robust when kept dry, cold and dark, and a desiccated powder stored at minus twenty degrees Celsius or below is generally expected to retain its chemical integrity for extended periods. In solution the peptide is far less stable, with degradation proceeding through oxidation of tryptophan and histidine residues, hydrolysis adjacent to the lactam bridge, and aggregation at higher concentrations. Repeated freeze-thaw cycling accelerates loss of the parent peak. Working aliquots are therefore prepared once, held cold, and used without letting the stock return to ambient temperature.
Quality assessment of research-grade peptide rests mainly on reversed-phase high-performance liquid chromatography for purity and on mass spectrometry for identity confirmation. A single main peak above a stated threshold, commonly ninety-eight percent by peak area, is the usual release criterion applied by suppliers. Independent analyses commissioned by laboratories and consumer organisations have repeatedly reported discrepancies between label claims and measured content, including truncated sequences, residual trifluoroacetate, and lower-than-declared peptide mass. Those findings do not establish that every supplier is unreliable, but they indicate that purity figures printed on a vial are claims requiring verification rather than settled facts.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
Human data remain limited and mostly short-term. Reports describe small trials and observational accounts rather than large controlled studies, so questions about dose-response relationships and long-term effects on melanocytes stay open. Whether repeated exposure alters naevus behaviour is not settled in the published record. Researchers also note that self-administered use outside clinical settings makes actual exposure difficult to quantify. Statements about efficacy and safety should therefore be read as preliminary rather than established.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
== Contraindications == Pentoxyverine is contraindicated in persons with bronchial asthma or other kinds of respiratory insufficiency (breathing difficulties), as well as angle-closure glaucoma. No data are available for the use of pentoxyverine during pregnancy, lactation, or children under two years of age, wherefore the drug must not be used under these circumstances. Antitussive drugs are not useful in patients with extensive phlegm production because they prevent coughing up the phlegm.
== Overdose == Enobosarm has been assessed in clinical trials at doses ranging from 0.1 to 18 mg/day. However, most research has been done at doses of 0.1 to 3 mg/day, with two phase 3 clinical trials using a dosage of 3 mg/day. A few small phase 1 and phase 2 trials of enobosarm for breast cancer have employed doses of 9 to 18 mg/day. Larger, phase 3 trials of enobosarm at a dose of 9 mg/day for breast cancer (e.g., ARTEST, n=210) are now underway. Doses of up to 100 mg have been assessed in single-dose pharmacokinetic studies and doses of up to 30 mg/day have been given in short 14-day pharmacokinetic studies. Enobosarm sold via black-market Internet suppliers and used non-medically is often taken at much higher doses than those used widely in clinical trials (e.g., 10–30 mg/day), with unknown adverse effects and risks.
^ Pesek, J. J.; Matyska, M. T.; Prabhakaran, S. J. (2005). "Synthesis and characterization of chemically bonded stationary phases on hydride surfaces by hydrosilation of alkynes and dienes". Journal of Separation Science. 28 (18): 2437–43. doi:10.1002/jssc.200500249. PMID 16405172. ^ Pesek, J. J.; Matyska, M. T.; Gangakhedkar, S.; Siddiq, R. (2006). "Synthesis and HPLC evaluation of carboxylic acid phases on a hydride surface". Journal of Separation Science. 29 (6): 872–80. doi:10.1002/jssc.200500433. PMID 16830499. ^ Hemström, P.; Irgum, K. (2006). "Hydrophilic interaction chromatography". Journal of Separation Science. 29 (12): 1784–821. doi:10.1002/jssc.200600199. PMID 16970185. ^ C. Kulsing, Y. Nolvachai, P.J. Marriott, R.I. Boysen, M.T. Matyska, J.J. Pesek, M.T.W. Hearn, J. Phys. Chem B, 119 (2015) 3063-3069. ^ J. Soukup, P. Janas, P. Jandera, J. Chromatogr. A, 1286 (2013) 111-118
Sources: en.wikipedia.org
=== In apricot === Apricot as a climacteric fruit undergoes fast post-harvest maturation. The latent PPO form can spontaneously activate during the first weeks of storage, generating the active enzyme with a molecular weight of 38 kDa. Ascorbic acid/protease combinations constitute a promising practical anti-browning method as treated apricot purees preserved their color.
== Example partition coefficient data == The values for the octanol-water system in the following table are from the Dortmund Data Bank. They are sorted by the partition coefficient, smallest to largest (acetamide being hydrophilic, and 2,2',4,4',5-pentachlorobiphenyl lipophilic), and are presented with the temperature at which they were measured (which impacts the values).
=== Classification of metal ions === Ahrland, Chatt and Davies proposed that metal ions could be described as class A if they formed stronger complexes with ligands whose donor atoms are nitrogen, oxygen or fluorine than with ligands whose donor atoms are phosphorus, sulfur or chlorine and class B if the reverse is true. For example, Ni2+ forms stronger complexes with amines than with phosphines, but Pd2+ forms stronger complexes with phosphines than with amines. Later, Pearson proposed the theory of hard and soft acids and bases (HSAB theory). In this classification, class A metals are hard acids and class B metals are soft acids. Some ions, such as copper(I), are classed as borderline. Hard acids form stronger complexes with hard bases than with soft bases. In general terms hard–hard interactions are predominantly electrostatic in nature whereas soft–soft interactions are predominantly covalent in nature. The HSAB theory, though useful, is only semi-quantitative. The hardness of a metal ion increases with oxidation state. An example of this effect is given by the fact that Fe2+ tends to form stronger complexes with N-donor ligands than with O-donor ligands, but the opposite is true for Fe3+.
Sources: en.wikipedia.org
== Side effects == Side effects of fentanyl analogs are similar to those of fentanyl itself, which include itching, nausea and potentially serious respiratory depression, which can be life-threatening. Fentanyl analogs have killed hundreds of people throughout Europe and the former Soviet republics since the most recent resurgence in use began in Estonia in the early 2000s, and novel derivatives continue to appear. A new wave of fentanyl analogues and associated deaths began in around 2014 in the US, and have continued to grow in prevalence; especially since 2016 these drugs have been responsible for hundreds of overdose deaths every week.
== Evolutionary origins == Synovial joints have been found in the earliest jawed vertebrates (gnathostomes) 400 million years ago during the Silurian and Devonian. This finding overturns an earlier view that these joints first evolved in early tetrapods for terrestrial locomotion. Comparative studies find that synovial joints are present in all major groups of jawed vertebrates, including cartilaginous fishes (sharks, skates, and rays), bony fishes, and tetrapods. They are, however, absent in jawless vertebrates such as lampreys and hagfish. Cartilaginous fishes have true synovial joints with clear synovial cavities, articular cartilage lined by flattened chondrocytes, and express key developmental signaling molecules including growth differentiation factor-5 (Gdf5) and β-catenin, and require muscle contraction for proper joint cavitation. In contrast, cyclostomes have joints filled with tissue rather than fluid-filled cavities, with proteoglycans uniformly distributed across cartilages. Fossil evidence finds jawless osteostracans had pectoral fin connections filled with canals incompatible with fluid-filled joint cavities, while early jawed placoderms have reciprocally articulating surfaces separated by joint cavities. Synovial joints, it has been suggested, arose due to the high mechanical loads associated with predation and feeding and, as a result, allowed for the evolution of the complex skeletons of modern jawed vertebrates.
Indeed, according to Williams, the goal of this analysis is to understand how suffering arises for sentient beings through an impersonal law and thus how it can also be brought to an end by reversing its causes. Understood in this way, dependent origination has no place for a creator God nor the ontological Vedic concept called universal Self (Brahman) nor any other 'transcendent creative principle'. In this worldview, there is no 'first cause' from which all beings arose, instead, every thing arises in dependence on something else. Though Eviatar Shulman sees dependent origination as mainly being concerned with mental processes, he also states that it "possessed important ontological implications" which "suggest that rather than things being conditioned by other things, they are actually conditioned by consciousness." This is implied by the fact that form (rūpa) is said to be conditioned by consciousness and willed activities (saṇkhara) as well as by how grasping is said to condition existence (bhava). For Shulman, "these forms of conditioning undermine the realistic ontology normally attributed to early Buddhism" and furthermore "suggest that the mind has power over objects beyond what we normally believe" as well as implying that "ontology is secondary to experience." While some scholars have argued that the Buddha put aside all metaphysical questions, Noa Ronkin argues that, while he rejected certain metaphysical questions, he was not an anti-metaphysician: nothing in the texts suggests that metaphysical questions are completely meaningless.
Cases of stigmatism fall into two categories: self-inflicted wounds, which may be either cases of fraud or of unconscious self-infliction, and those that are caused by emotional states ... Self-induced (through autosuggestion) itching and subsequent scratching of which the individual is unaware is likely to occur in suggestible persons if the stimulus is a mental or actual picture of the Crucifixion used during meditation and if the main motive is to receive the stigmata. The motive behind that may be unconscious conflict and a desire to escape from an intolerable situation into invalidism where one's needs are taken care of. It then becomes a case of hysterical conversion reaction. Many cases of stigmatism can be explained as fraud or unconsciously self-inflicted wounds. In his Stigmata: A Medieval Phenomenon in a Modern Age, Ted Harrison suggests that there is no single mechanism whereby the marks of stigmata were produced. Harrison found no evidence from a study of contemporary cases that the marks were supernatural in origin. He concluded, however, that marks of natural origin need not be hoaxes. Some stigmatics marked themselves in attempt to suffer with Christ as a form of piety. Others marked themselves accidentally and their marks were noted as stigmata by witnesses. Often marks of human origin produced profound and genuine religious responses. Harrison also noted that after Saint Francis of Assisi, the stigmata was "seen as a predominantly female experience" with the female-to-male ratio of stigmatics being 7 to 1.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
Solutions are best kept cold, protected from light, and buffered to a pH that limits hydrolysis. Dividing a stock into single-use aliquots avoids repeated freeze-thaw cycles, which measurably reduce the intact parent peak over time.